<DOC>
	<DOCNO>NCT00779428</DOCNO>
	<brief_summary>The primary purpose study provide treatment patient participate prior protocol investigate Tanespimycin ( KOS-953,17-AAG )</brief_summary>
	<brief_title>Clinical Trial Continuing Treatment Patients Who Have Participated Prior Protocol Investigating Tanespimycin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age &gt; = 18 year Participated complete previous Tanespimycin protocol without evidence unacceptable toxicity deem Investigator derive benefit Tanespimycin drug define previous protocol All patient must rollover continuation protocol within 30 day last dose Tanespimycin previous protocol , unless previously approve Medical Monitor All Adverse Events prior protocol , must resolve NCI CTCAE ( v. 3.0 ) Grade &lt; = 2 The following laboratory result , within 10 day Tanespimycin administration : Hemoglobin &gt; = 8 g/dL Absolute neutrophils count &gt; = 1.0x 10*9* /L Platelet count &gt; = 50 x 10*9* /L Serum bilirubin &lt; = 2 x ULN AST &lt; = 2.5 ULN Serum creatinine &lt; = 2 x ULN ECOG performance status 0 , 1 2 Signed inform consent Preexisting neuropathy CTCAE Grade &gt; = 3 due cause Documented hypersensitivity reaction CTCAE Grade &gt; = 3 prior therapy contain Cremophor ( patient receive Tanespimycin Injection ) Pregnant breastfeed woman Administration chemotherapy , biological , immunotherapy investigational agent ( therapeutic diagnostic ) , exclude Tanespimycin within 21 day prior receipt study medication Any medical condition , Investigator 's opinion , would impose excessive risk patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>This open-label continue treatment protocol patient advanced malignancy receive Tanespimycin</keyword>
</DOC>